Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials

Kennedy R. Lees, Erich Bluhmki, Rüdiger von Kummer, Thomas G Brott, Danilo Toni, James C. Grotta, Gregory W. Albers, Markku Kaste, John R. Marler, Scott A. Hamilton, Barbara C. Tilley, Stephen M. Davis, Geoffrey A. Donnan, Werner Hacke

Research output: Contribution to journalArticle

1348 Citations (Scopus)

Abstract

Background: Early administration of intravenous recombinant tissue plasminogen activator (rt-PA) after ischaemic stroke improves outcome. Previous analysis of combined data from individual patients suggested potential benefit beyond 3 h from stroke onset. We re-examined the effect of time to treatment with intravenous rt-PA (alteplase) on therapeutic benefit and clinical risk by adding recent trial data to the analysis. Methods: We added data from ECASS III (821 patients) and EPITHET (100 patients) to a pool of common data elements from six other trials of alteplase for acute stroke (2775 patients). We used multivariate logistic regression to assess the relation of stroke onset to start of treatment (OTT) with treatment on favourable 3-month outcome (defined as modified Rankin score 0-1), mortality, and occurrence and outcome of clinically relevant parenchymal haemorrhage. The presence of an arterial occlusion was inferred from the patient's symptoms and absence of haemorrhage or other causes of ischaemic stroke. Vascular imaging was not a requirement in the trials. All patients with confirmed OTT within 360 min were included in the analysis. Findings: Treatment was started within 360 min of stroke onset in 3670 patients randomly allocated to alteplase (n=1850) or to placebo (n=1820). Odds of a favourable 3-month outcome increased as OTT decreased (p=0·0269) and no benefit of alteplase treatment was seen after around 270 min. Adjusted odds of a favourable 3-month outcome were 2·55 (95% CI 1·44-4·52) for 0-90 min, 1·64 (1·12-2·40) for 91-180 min, 1·34 (1·06-1·68) for 181-270 min, and 1·22 (0·92-1·61) for 271-360 min in favour of the alteplase group. Large parenchymal haemorrhage was seen in 96 (5·2%) of 1850 patients assigned to alteplase and 18 (1·0%) of 1820 controls, with no clear relation to OTT (p=0·4140). Adjusted odds of mortality increased with OTT (p=0·0444) and were 0·78 (0·41-1·48) for 0-90 min, 1·13 (0·70-1·82) for 91-180 min, 1·22 (0·87-1·71) for 181-270 min, and 1·49 (1·00-2·21) for 271-360 min. Interpretation: Patients with ischaemic stroke selected by clinical symptoms and CT benefit from intravenous alteplase when treated up to 4·5 h. To increase benefit to a maximum, every effort should be taken to shorten delay in initiation of treatment. Beyond 4·5 h, risk might outweigh benefit. Funding: None.

Original languageEnglish (US)
Pages (from-to)1695-1703
Number of pages9
JournalThe Lancet
Volume375
Issue number9727
DOIs
StatePublished - 2010

Fingerprint

National Institute of Neurological Disorders and Stroke
Tissue Plasminogen Activator
Stroke
Therapeutics
Hemorrhage
Mortality
Intravenous Administration
Blood Vessels

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Time to treatment with intravenous alteplase and outcome in stroke : an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. / Lees, Kennedy R.; Bluhmki, Erich; von Kummer, Rüdiger; Brott, Thomas G; Toni, Danilo; Grotta, James C.; Albers, Gregory W.; Kaste, Markku; Marler, John R.; Hamilton, Scott A.; Tilley, Barbara C.; Davis, Stephen M.; Donnan, Geoffrey A.; Hacke, Werner.

In: The Lancet, Vol. 375, No. 9727, 2010, p. 1695-1703.

Research output: Contribution to journalArticle

Lees, KR, Bluhmki, E, von Kummer, R, Brott, TG, Toni, D, Grotta, JC, Albers, GW, Kaste, M, Marler, JR, Hamilton, SA, Tilley, BC, Davis, SM, Donnan, GA & Hacke, W 2010, 'Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials', The Lancet, vol. 375, no. 9727, pp. 1695-1703. https://doi.org/10.1016/S0140-6736(10)60491-6
Lees, Kennedy R. ; Bluhmki, Erich ; von Kummer, Rüdiger ; Brott, Thomas G ; Toni, Danilo ; Grotta, James C. ; Albers, Gregory W. ; Kaste, Markku ; Marler, John R. ; Hamilton, Scott A. ; Tilley, Barbara C. ; Davis, Stephen M. ; Donnan, Geoffrey A. ; Hacke, Werner. / Time to treatment with intravenous alteplase and outcome in stroke : an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. In: The Lancet. 2010 ; Vol. 375, No. 9727. pp. 1695-1703.
@article{1e2f273ef4914a6bb1e4c8ee036f302f,
title = "Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials",
abstract = "Background: Early administration of intravenous recombinant tissue plasminogen activator (rt-PA) after ischaemic stroke improves outcome. Previous analysis of combined data from individual patients suggested potential benefit beyond 3 h from stroke onset. We re-examined the effect of time to treatment with intravenous rt-PA (alteplase) on therapeutic benefit and clinical risk by adding recent trial data to the analysis. Methods: We added data from ECASS III (821 patients) and EPITHET (100 patients) to a pool of common data elements from six other trials of alteplase for acute stroke (2775 patients). We used multivariate logistic regression to assess the relation of stroke onset to start of treatment (OTT) with treatment on favourable 3-month outcome (defined as modified Rankin score 0-1), mortality, and occurrence and outcome of clinically relevant parenchymal haemorrhage. The presence of an arterial occlusion was inferred from the patient's symptoms and absence of haemorrhage or other causes of ischaemic stroke. Vascular imaging was not a requirement in the trials. All patients with confirmed OTT within 360 min were included in the analysis. Findings: Treatment was started within 360 min of stroke onset in 3670 patients randomly allocated to alteplase (n=1850) or to placebo (n=1820). Odds of a favourable 3-month outcome increased as OTT decreased (p=0·0269) and no benefit of alteplase treatment was seen after around 270 min. Adjusted odds of a favourable 3-month outcome were 2·55 (95{\%} CI 1·44-4·52) for 0-90 min, 1·64 (1·12-2·40) for 91-180 min, 1·34 (1·06-1·68) for 181-270 min, and 1·22 (0·92-1·61) for 271-360 min in favour of the alteplase group. Large parenchymal haemorrhage was seen in 96 (5·2{\%}) of 1850 patients assigned to alteplase and 18 (1·0{\%}) of 1820 controls, with no clear relation to OTT (p=0·4140). Adjusted odds of mortality increased with OTT (p=0·0444) and were 0·78 (0·41-1·48) for 0-90 min, 1·13 (0·70-1·82) for 91-180 min, 1·22 (0·87-1·71) for 181-270 min, and 1·49 (1·00-2·21) for 271-360 min. Interpretation: Patients with ischaemic stroke selected by clinical symptoms and CT benefit from intravenous alteplase when treated up to 4·5 h. To increase benefit to a maximum, every effort should be taken to shorten delay in initiation of treatment. Beyond 4·5 h, risk might outweigh benefit. Funding: None.",
author = "Lees, {Kennedy R.} and Erich Bluhmki and {von Kummer}, R{\"u}diger and Brott, {Thomas G} and Danilo Toni and Grotta, {James C.} and Albers, {Gregory W.} and Markku Kaste and Marler, {John R.} and Hamilton, {Scott A.} and Tilley, {Barbara C.} and Davis, {Stephen M.} and Donnan, {Geoffrey A.} and Werner Hacke",
year = "2010",
doi = "10.1016/S0140-6736(10)60491-6",
language = "English (US)",
volume = "375",
pages = "1695--1703",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9727",

}

TY - JOUR

T1 - Time to treatment with intravenous alteplase and outcome in stroke

T2 - an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials

AU - Lees, Kennedy R.

AU - Bluhmki, Erich

AU - von Kummer, Rüdiger

AU - Brott, Thomas G

AU - Toni, Danilo

AU - Grotta, James C.

AU - Albers, Gregory W.

AU - Kaste, Markku

AU - Marler, John R.

AU - Hamilton, Scott A.

AU - Tilley, Barbara C.

AU - Davis, Stephen M.

AU - Donnan, Geoffrey A.

AU - Hacke, Werner

PY - 2010

Y1 - 2010

N2 - Background: Early administration of intravenous recombinant tissue plasminogen activator (rt-PA) after ischaemic stroke improves outcome. Previous analysis of combined data from individual patients suggested potential benefit beyond 3 h from stroke onset. We re-examined the effect of time to treatment with intravenous rt-PA (alteplase) on therapeutic benefit and clinical risk by adding recent trial data to the analysis. Methods: We added data from ECASS III (821 patients) and EPITHET (100 patients) to a pool of common data elements from six other trials of alteplase for acute stroke (2775 patients). We used multivariate logistic regression to assess the relation of stroke onset to start of treatment (OTT) with treatment on favourable 3-month outcome (defined as modified Rankin score 0-1), mortality, and occurrence and outcome of clinically relevant parenchymal haemorrhage. The presence of an arterial occlusion was inferred from the patient's symptoms and absence of haemorrhage or other causes of ischaemic stroke. Vascular imaging was not a requirement in the trials. All patients with confirmed OTT within 360 min were included in the analysis. Findings: Treatment was started within 360 min of stroke onset in 3670 patients randomly allocated to alteplase (n=1850) or to placebo (n=1820). Odds of a favourable 3-month outcome increased as OTT decreased (p=0·0269) and no benefit of alteplase treatment was seen after around 270 min. Adjusted odds of a favourable 3-month outcome were 2·55 (95% CI 1·44-4·52) for 0-90 min, 1·64 (1·12-2·40) for 91-180 min, 1·34 (1·06-1·68) for 181-270 min, and 1·22 (0·92-1·61) for 271-360 min in favour of the alteplase group. Large parenchymal haemorrhage was seen in 96 (5·2%) of 1850 patients assigned to alteplase and 18 (1·0%) of 1820 controls, with no clear relation to OTT (p=0·4140). Adjusted odds of mortality increased with OTT (p=0·0444) and were 0·78 (0·41-1·48) for 0-90 min, 1·13 (0·70-1·82) for 91-180 min, 1·22 (0·87-1·71) for 181-270 min, and 1·49 (1·00-2·21) for 271-360 min. Interpretation: Patients with ischaemic stroke selected by clinical symptoms and CT benefit from intravenous alteplase when treated up to 4·5 h. To increase benefit to a maximum, every effort should be taken to shorten delay in initiation of treatment. Beyond 4·5 h, risk might outweigh benefit. Funding: None.

AB - Background: Early administration of intravenous recombinant tissue plasminogen activator (rt-PA) after ischaemic stroke improves outcome. Previous analysis of combined data from individual patients suggested potential benefit beyond 3 h from stroke onset. We re-examined the effect of time to treatment with intravenous rt-PA (alteplase) on therapeutic benefit and clinical risk by adding recent trial data to the analysis. Methods: We added data from ECASS III (821 patients) and EPITHET (100 patients) to a pool of common data elements from six other trials of alteplase for acute stroke (2775 patients). We used multivariate logistic regression to assess the relation of stroke onset to start of treatment (OTT) with treatment on favourable 3-month outcome (defined as modified Rankin score 0-1), mortality, and occurrence and outcome of clinically relevant parenchymal haemorrhage. The presence of an arterial occlusion was inferred from the patient's symptoms and absence of haemorrhage or other causes of ischaemic stroke. Vascular imaging was not a requirement in the trials. All patients with confirmed OTT within 360 min were included in the analysis. Findings: Treatment was started within 360 min of stroke onset in 3670 patients randomly allocated to alteplase (n=1850) or to placebo (n=1820). Odds of a favourable 3-month outcome increased as OTT decreased (p=0·0269) and no benefit of alteplase treatment was seen after around 270 min. Adjusted odds of a favourable 3-month outcome were 2·55 (95% CI 1·44-4·52) for 0-90 min, 1·64 (1·12-2·40) for 91-180 min, 1·34 (1·06-1·68) for 181-270 min, and 1·22 (0·92-1·61) for 271-360 min in favour of the alteplase group. Large parenchymal haemorrhage was seen in 96 (5·2%) of 1850 patients assigned to alteplase and 18 (1·0%) of 1820 controls, with no clear relation to OTT (p=0·4140). Adjusted odds of mortality increased with OTT (p=0·0444) and were 0·78 (0·41-1·48) for 0-90 min, 1·13 (0·70-1·82) for 91-180 min, 1·22 (0·87-1·71) for 181-270 min, and 1·49 (1·00-2·21) for 271-360 min. Interpretation: Patients with ischaemic stroke selected by clinical symptoms and CT benefit from intravenous alteplase when treated up to 4·5 h. To increase benefit to a maximum, every effort should be taken to shorten delay in initiation of treatment. Beyond 4·5 h, risk might outweigh benefit. Funding: None.

UR - http://www.scopus.com/inward/record.url?scp=77952112006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952112006&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(10)60491-6

DO - 10.1016/S0140-6736(10)60491-6

M3 - Article

C2 - 20472172

AN - SCOPUS:77952112006

VL - 375

SP - 1695

EP - 1703

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9727

ER -